GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Change In Payables And Accrued Expense

Concord Biotech (BOM:543960) Change In Payables And Accrued Expense : ₹0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Change In Payables And Accrued Expense?

Concord Biotech's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Concord Biotech's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Mar. 2024 .

Concord Biotech's Change In Payables And Accrued Expense for the fiscal year that ended in Mar. 2024 was ₹0 Mil. It means Concord Biotech's Accounts Payable & Accrued Expense stayed the same from Mar. 2023 to Mar. 2024 .

Concord Biotech Change In Payables And Accrued Expense Historical Data

The historical data trend for Concord Biotech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Change In Payables And Accrued Expense Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Change In Payables And Accrued Expense
- - - - -

Concord Biotech Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial - - - - -

Concord Biotech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech (BOM:543960) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
BOM:540701 BOM:543434 NSE:ZOTA BOM:531349 NSE:BALAXI BOM:500259 BOM:524717 BOM:532890 BOM:540679 BOM:524663 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CONCORDBIO:India
Address
Iscon Cross Road, S.G. Highway, 16th floor, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Website
https://www.concordbiotech.com
Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Concord Biotech (BOM:543960) Headlines

No Headlines